NYSE
17.32USD
+0.08 (+0.46%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.2B
P/E
—
EPS
—
Beta
0.55
52W range
13.765-18.915
Day range
17.22–17.56
Open
17.32
Prev close
17.24
Volume
290.5K
Avg volume
439.2K
Dividend
0.00
IPO
2022-05-06
https://www.marketbeat.com/instant-alerts/event-bausch-lomb-advances-dry-eye-drug-to-phase-iii-as-pain-candidate-hits-phase-ib-goal-2026-08-24/ · 8/25/2026+0.60
https://www.zacks.com/stock/news/2945711/is-coo-stock-attractive-as-myday-gains-meet-asia-pacific-pressure?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2945711 · 6/30/2026+0.00
https://www.zacks.com/stock/news/2934890/alignment-healthcare-alhc-soars-25-1-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2934890 · 6/10/2026+0.20
https://seekingalpha.com/article/4913439-bausch-lomb-corporation-blco-presents-at-goldman-sachs-47th-annual-global-healthcare · 6/9/2026+0.20
https://seekingalpha.com/article/4910716-bausch-lomb-corporation-blco-discusses-project-halo-and-myopia-control-developments-in-vision · 6/1/2026+0.60
https://www.businesswire.com/news/home/20260330662557/en/Bausch-Lomb-Will-Release-First-Quarter-2026-Financial-Results-on-April-29/ · 3/30/2026+0.00
https://www.fool.com/coverage/filings/2026/03/24/a-bausch-lomb-director-just-bought-usd77-000-in-stock-that-s-only-half-the-story/ · 3/24/2026+0.30
https://seekingalpha.com/article/4885083-bausch-lomb-corporation-blco-discusses-glaucoma-pipeline-focus-with-updates-on-bl1107-and · 3/24/2026+0.40
https://www.fool.com/coverage/filings/2026/03/12/eye-care-giant-posts-usd5-1-billion-in-revenue-as-one-investor-builds-major-position/ · 3/12/2026+0.80
https://seekingalpha.com/article/4872379-bausch-lomb-q4-earnings-review-still-a-buy-with-some-caveats · 2/19/2026+1.00
https://seekingalpha.com/article/4844833-bausch-lomb-corporation-blco-bausch-lomb-corporation-analyst-investor-day-transcript · 11/18/2025+0.00
https://www.businesswire.com/news/home/20251103960406/en/Bausch-Lomb-to-Hold-Investor-Day-on-Nov.-13/ · 11/3/2025+0.20
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works